GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Other Net Income (Loss)

Shire (SHPG) Other Net Income (Loss) : $13 Mil (TTM As of Sep. 2018)


View and export this data going back to 1998. Start your Free Trial

What is Shire Other Net Income (Loss)?

Shire's Other Net Income (Loss) for the three months ended in Sep. 2018 was $5 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2018 was $13 Mil.

Shire's quarterly Other Net Income (Loss) increased from Mar. 2018 ($1 Mil) to Jun. 2018 ($6 Mil) but then declined from Jun. 2018 ($6 Mil) to Sep. 2018 ($5 Mil).

Shire's annual Other Net Income (Loss) declined from Dec. 2015 ($-36 Mil) to Dec. 2016 ($-285 Mil) but then increased from Dec. 2016 ($-285 Mil) to Dec. 2017 ($21 Mil).


Shire Other Net Income (Loss) Historical Data

The historical data trend for Shire's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Other Net Income (Loss) Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -750.60 125.40 -36.30 -284.80 20.50

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.80 1.80 0.80 5.70 4.70

Shire Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shire Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Shire's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Shire (SHPG) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Executives
James H Cavanaugh director 265 HOTHORPE LANE, VILLANOVA PA 19085

Shire (SHPG) Headlines

From GuruFocus

Takeda Closes In on Shire, But It's Not a Done Deal Yet

By John Engle John Engle 05-08-2018